NCT05414123 - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 7, 2022

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions

Leptomeningeal MetastasisLeptomeningeal DiseaseLeptomeningeal NeoplasmsBreast CancerNon-Small Cell Lung Cancer

Interventions

DEVICE

CNSide

The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.

Trial Locations (4)

60611

Northwestern University Feinberg School of Medicine, Chicago

94305

Stanford University, Stanford

98109

University of Washington, Seattle

75235-1979

The University of Texas Southwestern Medical Center, Dallas